Abstract
Patients with rheumatoid arthritis (RA) occasionally have osteoporosis (OP) as a comorbidity. This condition is brought on by glucocorticoid medication, decreased mobility, chronic inflammation, and other disease-related causes. This narrative review aimed to provide an overview of the most recent data regarding pharmacological treatment options for RA patients with OP. Through reviewing the research published during the last 15 years, a thorough search of the PubMed, Scopus, and Web of Science databases was carried out. According to the literature, RA patients are far more likely than the general population to experience fragility fractures and decreased bone mineral density. Early screening with dual-energy x-ray absorptiometry, RA disease control optimization, sufficient calcium and vitamin D intake, lifestyle changes, and pharmaceutical treatments such as bisphosphonates, denosumab, and parathyroid hormone analogs are all examples of effective management techniques. Optimizing patient outcomes requires multidisciplinary care from physiotherapists, endocrinologists, and rheumatologists. For best results, RA and OP management must be integrated, as well as patient education and adherence techniques. Early detection and personalized treatment of OP in RA patients can significantly lower the fracture risk, preserve functional independence, and enhance the quality of life.

Key words: Rheumatoid arthritis, osteoporosis, bone mineral density, fracture prevention, narrative review